1. Search Result
Search Result
Results for "

HT1

" in MedChemExpress (MCE) Product Catalog:

422

Inhibitors & Agonists

1

Screening Libraries

2

Peptides

9

Natural
Products

51

Isotope-Labeled Compounds

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0607
    Nitisinone
    2 Publications Verification

    NTBC; Nitisone; SC0735

    HPPD Metabolic Disease
    Nitisinone is an orally active, competitive and reversible 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) inhibitor with an IC50 of 173 nM. Nitisinone promotes tyrosine accumulation in a dose-dependent manner. nitisinone can be used in studies of hereditary tyrosinemia type 1 (HT-1) (a rare genetic disorder) and albinism [1] .
    Nitisinone
  • HY-B0197A
    Naratriptan hydrochloride
    2 Publications Verification

    GR-85548A hydrochloride

    5-HT Receptor Neurological Disease
    Naratriptan hydrochloride is a selective 5-HT1 receptor subtype agonist and is a triptan drug that is used for the treatment of migraine headaches.
    Naratriptan hydrochloride
  • HY-101583

    SPI-376

    5-HT Receptor GABA Receptor Dopamine Receptor Neurological Disease
    NEO 376 is a selective modulator of 5-HT1 receptor, GABA receptor and dopamine receptor, with anti-psychotic actively.
    NEO 376
  • HY-15688
    8-OH-DPAT hydrobromide
    3 Publications Verification

    8-Hydroxy-DPAT hydrobromide

    5-HT Receptor Neurological Disease
    8-OH-DPAT (8-Hydroxy-DPAT) hydrobromide is a potent and selective 5-HT1A agonist with a pIC50 of 8.19. 8-OH-DPAT hydrobromide has selectivity of almost 1000 fold for a subtype of the 5-HT1 binding site [1].
    8-OH-DPAT hydrobromide
  • HY-B0607R

    NTBC (Standard); Nitisone (Standard); SC56735 (Standard)

    HPPD Metabolic Disease
    Nitisinone (Standard) is the analytical standard of Nitisinone. This product is intended for research and analytical applications. Nitisinone is an orally active, competitive and reversible 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) inhibitor with an IC50 of 173 nM. Nitisinone promotes tyrosine accumulation in a dose-dependent manner. nitisinone can be used in studies of hereditary tyrosinemia type 1 (HT-1) (a rare genetic disorder) and albinism [1] .
    Nitisinone (Standard)
  • HY-B0197

    GR-85548A

    5-HT Receptor Neurological Disease
    Naratriptan is a selective 5-HT1 receptor subtype agonist and is a triptan drug that is used for the treatment of migraine headaches.
    Naratriptan
  • HY-B0197AS

    GR-85548A d3

    Isotope-Labeled Compounds 5-HT Receptor Neurological Disease
    Naratriptan-d3 (hydrochloride) is the deuterium labeled Naratriptan, which is a selective 5-HT1 receptor subtype agonist.
    Naratriptan-d3 hydrochloride
  • HY-106124

    5-HT Receptor Cardiovascular Disease
    IS-159 is a potent serotonin 5-HT1 agonist. IS-159 has the potential for the research of migraine [1].
    IS-159
  • HY-B0197S

    GR-85548A-d3-1

    5-HT Receptor Neurological Disease
    Naratriptan-d3 is the deuterium labeled Naratriptan[1]. Naratriptan is a selective 5-HT1 receptor subtype agonist[2].
    Naratriptan-d3
  • HY-B0206S

    Isotope-Labeled Compounds 5-HT Receptor Neurological Disease
    Rizatriptan-d6 (benzoate) is the deuterium labeled Rizatriptan benzoate. Rizatriptan benzoate is a 5-HT1 agonist triptan agent for the treatment of migraine headaches[1][2].
    Rizatriptan-d6 benzoate
  • HY-B2089

    5-HT Receptor Dopamine Receptor Neurological Disease Metabolic Disease
    Cinitapride is a nonselective 5-HT1 and 5-HT4 receptors agonist and a 5-HT2 and D2 antagonist. Cinitapride can be used in functional dyspepsia (FD) and gastroesophageal reflux disease (GERD) research [1].
    Cinitapride
  • HY-135021

    5-HT Receptor Others
    3,4-Dihydro Naratriptan is a serotonin 5-HT1-receptor agonist. 3,4-Dihydro Naratriptan exhibits selective vasoconstrictor activity. 3,4-Dihydro Naratriptan can be used for migraine diseases research [1].
    3,4-Dihydro Naratriptan
  • HY-W022362

    Serotonin Transporter Neurological Disease
    2-Aminotetralin is a potent and selective serotonin 5-HT1 agonist. 2-Aminotetralin exhibits high affinity (Ki≤25 nM) and at least 50-fold stereoselective preference at 5-HT1A, 5-HT1B, and 5-HT1D receptors [1].
    2-Aminotetralin
  • HY-B0121B
    Sumatriptan
    4 Publications Verification

    GR 43175 free base

    5-HT Receptor Neurological Disease
    Sumatriptan (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan can be used for migraine headache research [1] .
    Sumatriptan
  • HY-B0121A

    GR 43175 hydrochloride

    5-HT Receptor Neurological Disease
    Sumatriptan hydrochloride (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan hydrochloride can be used for migraine headache research [1] .
    Sumatriptan hydrochloride
  • HY-106805

    5-HT Receptor Others
    ICI 169369 is an orally active, specific serotonin and 5-HT2/5-HT1C receptor competitive antagonist. ICI 169369 exhibits Ki values of 1.79 x 10 −8 and 1.58 x 10 −6 M for 5-HT2 and 5-HT1, respectively [1] .
    ICI 169369
  • HY-44132

    RS 42358-197

    5-HT Receptor Neurological Disease
    Dehydro Palonosetron (RS 42358-197) is a potent, seslective and orally active 5-HT3 receptor antagonist. Dehydro Palonosetron has no effect on the activities of 5-HT1 receptors, 5-HT2 receptors or 5-HT4 receptors [1].
    Dehydro Palonosetron
  • HY-106484

    BAY-P 4495

    5-HT Receptor Neurological Disease
    Tiflucarbine (BAY-P 4495) is a tetrahydrothieno-7-carboline derivative. Tiflucarbine is a potent antidepressant agent that binds at central serotonin (5-HT) binding sites. Tiflucarbine is a nonselective 5-HT (5-HT1 and 5-HT2) agonist [1] .
    Tiflucarbine
  • HY-B0121BS
    Sumatriptan-d6 succinate
    1 Publications Verification

    GR 43175C-d6

    5-HT Receptor Isotope-Labeled Compounds Neurological Disease
    Sumatriptan-d6 succinate is the deuterium labeled Sumatriptan succinate. Sumatriptan succinate is an orally active 5-HT1 receptor agonist with Kis of 17 nM, 27 nM and 100 nM for 5-HT1D, 5-HT1B and 5-HT1A receptors, respectively. Sumatriptan succinate can be used for migraine headache research [1] .
    Sumatriptan-d6 succinate
  • HY-B0121
    Sumatriptan succinate
    4 Publications Verification

    GR 43175 succinate

    5-HT Receptor Neurological Disease
    Sumatriptan succinate (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan succinate can be used for migraine headache research [1] .
    Sumatriptan succinate
  • HY-B0121R

    GR 43175 succinate (Standard)

    5-HT Receptor Neurological Disease
    Sumatriptan (succinate) (Standard) is the analytical standard of Sumatriptan (succinate). This product is intended for research and analytical applications. Sumatriptan succinate (GR 43175) is an orally active 5-HT1 receptor agonist with Kis of 17 nM, 27 nM and 100 nM for 5-HT1D, 5-HT1B and 5-HT1A receptors, respectively. Sumatriptan succinate can be used for migraine headache research [1] .
    Sumatriptan (succinate) (Standard)
  • HY-B2089R

    5-HT Receptor Dopamine Receptor Neurological Disease Metabolic Disease
    Cinitapride (Standard) is the analytical standard of Cinitapride. This product is intended for research and analytical applications. Cinitapride is a nonselective 5-HT1 and 5-HT4 receptors agonist and a 5-HT2 and D2 antagonist. Cinitapride can be used in functional dyspepsia (FD) and gastroesophageal reflux disease (GERD) research [1].
    Cinitapride (Standard)
  • HY-121562

    5-HT Receptor Neurological Disease
    SB 714786 is a potent and selective 5-hydroxytryptamine 1D (5-HT1D) receptor antagonist. It was developed from the previously reported series of dual 5-HT1 selective 5-hydroxytryptamine reuptake inhibitors (5HT1-SSRIs). SB 714786 is the first reported highly potent and selective 5-HT1D receptor antagonist, providing an extremely useful pharmacological tool for further understanding the role of 5-HT1 receptor subtypes. It has no or very low intrinsic activity against all three receptors. SB 714786 has pKi values of 6.5, 6.7, 9.1 and 6.5 for 5-HT1A, 5-HT1B, 5-HT1D and SerT receptors, respectively, showing high selectivity for 5-HT1D receptors. These properties make SB 714786 a potential tool compound for studying the function of 5-HT1D receptors and the treatment of related diseases.
    SB 714786
  • HY-B0121BS2

    GR 43175 free base-d5

    5-HT Receptor Isotope-Labeled Compounds Neurological Disease
    Sumatriptan-d5 is deuterated labeled Sumatriptan (HY-B0121B). Sumatriptan (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan can be used for migraine headache research [1] .
    Sumatriptan-d5
  • HY-B0121BS3

    GR 43175 free base-d6 formate

    Isotope-Labeled Compounds 5-HT Receptor Neurological Disease
    Sumatriptan-d6 (formate) (GR 43175 free base-d6 (formate)) is deuterium labeled Sumatriptan. Sumatriptan (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan can be used for migraine headache research [1] .
    Sumatriptan-d6 formate
  • HY-103151A

    5-HT Receptor Others
    CP94253 is a selective, orally active agonist for serotonin receptor 1B (5-HT1B), through competitive binding with iodocyanopindolol (ICP) to the 5-HT1 receptor. CP94253 binds to the 5-HT1B, 5-HT1A, 5-HT1D, 5-HT1C and 5-HT2 receptors, with Kis of 2, 89, 49, 860 and 1600 nM. CP94253 causes satiety, anorexia, weight loss and hyperlocomotion in rats model [1].
    CP94253
  • HY-100943
    Cinanserin hydrochloride
    1 Publications Verification

    SQ 10643

    5-HT Receptor Influenza Virus Infection Inflammation/Immunology
    Cinanserin hydrochloride (SQ 10643) is a potent, selective and highly affinity 5-HT2 receptor antagonist with a Ki of 41 nM. Cinanserin hydrochloride has a much higher binding affinity for the 5-HT2 than for the 5-HT1 receptor (Ki of 3500 nM). Cinanserin is also an inhibitor of 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro [1] .
    Cinanserin hydrochloride
  • HY-133828

    5-HT Receptor SARS-CoV Infection
    Cinanserin (SQ 10643) is a potent and selective 5-HT2 antagonist with Ki values of 41, 3500 nM for 5-HT2, 5-HT1, respectively. Cinanserin also is a SARS-CoV 3CL pro inhibitor with an KD value of 49.4, 18.2 µM for SARS-CoV 3CL pro, HCoV-229E 3CL pro, respectively. Cinanserin reduces systemic burn edema levels [1] .
    Cinanserin
  • HY-146201

    Phosphodiesterase (PDE) Others
    1 a /5-hydroxynitrile rubber 7 receptor antagonist (5-HT1 a k i = 8 nm, kb= 0.04 nm; 5-nitrile rubber 7K I = 451 nm, kb= 460 nm) has pde4b/pde7a inhibitory activity (PDE4B ic50= 80.4 μ M; Pde7a chip 50= 151.3 μ M)。 Compound 22 has a very good ability of passive penetration of biofilm and high metabolic stability in vitro. In addition, 22's pharmacological evaluation showed its pre cognitive and antidepressant properties in rat behavioral tests.
    PDE4B/7A-IN-1
  • HY-163101

    Platelet-activating Factor Receptor (PAFR) Leukotriene Receptor Inflammation/Immunology
    CP-96021 is a potent and orally available leukotriene D4 (LTD4 Ki=34 μM) / platelet activating factor (PAF Ki=37 μM) receptor antagonist. CP-96021 has antagonist capable of simultaneously targeting two different inflammatory mediators, LTD4 and PAF. CP-96021 shows high specificity for α1, α2, β, dopamine-2, adenosine 1, 5-HT1, H1, muscarine, μ opioid, and GABA receptors, all expressing IC50 values greater than 10 μM. CP-96021 can be used to study the pathogenesis of many inflammatory diseases such as asthma [1].
    CP-96021
  • HY-10564
    Sarpogrelate hydrochloride
    1 Publications Verification

    MCI-9042

    5-HT Receptor Cardiovascular Disease
    Sarpogrelate hydrochloride (MCI-9042) is a selective 5-HT2R antagonist, with pKis of 8.52, 6.57, and 7.43 for 5-HT2A, 5-HT2B, and 5-HT2C receptors, respectively. Sarpogrelate hydrochloride displays selectivity over 5-HT1, 5-HT3, 5-HT4, α1-, α2- and β-adrenoreceptor, histamine H1, H2 and muscarinic M3 receptors. Sarpogrelate hydrochloride can be used for the research of vascular disease associated with thrombosis [1] .
    Sarpogrelate hydrochloride
  • HY-144764

    5-HT Receptor Neurological Disease
    5-HT1A antagonist 1 (compound 6f) is a potent and selective antagonist of 5-HT1A receptor, with a Ki of 35 nM. 5-HT1A antagonist 1 can be used for the research of CNS diseases [1].
    5-HT1A antagonist 1
  • HY-10564S

    MCI-9042-d3

    Isotope-Labeled Compounds 5-HT Receptor Cardiovascular Disease
    Sarpogrelate-d3 (hydrochloride) is the deuterium labeled Sarpogrelate hydrochloride. Sarpogrelate hydrochloride (MCI-9042) is a selective 5-HT2R antagonist, with pKis of 8.52, 6.57, and 7.43 for 5-HT2A, 5-HT2B, and 5-HT2C receptors, respectively. Sarpogrelate hydrochloride displays selectivity over 5-HT1, 5-HT3, 5-HT4, α1-, α2- and β-adrenoreceptor, histamine H1, H2 and muscarinic M3 receptors. Sarpogrelate hydrochloride can be used for the research of vascular disease associated with thrombosis[1][2][3].
    Sarpogrelate-d3 hydrochloride
  • HY-10564S1

    MCI-9042-d4

    Isotope-Labeled Compounds 5-HT Receptor Cardiovascular Disease
    Sarpogrelate-d4 (MCI-9042-d4) hydrochloride is deuterium labeled Sarpogrelate (hydrochloride). Sarpogrelate hydrochloride (MCI-9042) is a selective 5-HT2R antagonist, with pKis of 8.52, 6.57, and 7.43 for 5-HT2A, 5-HT2B, and 5-HT2C receptors, respectively. Sarpogrelate hydrochloride displays selectivity over 5-HT1, 5-HT3, 5-HT4, α1-, α2- and β-adrenoreceptor, histamine H1, H2 and muscarinic M3 receptors. Sarpogrelate hydrochloride can be used for the research of vascular disease associated with thrombosis [1] .
    Sarpogrelate-d4 hydrochloride
  • HY-136621

    5-HT Receptor Neurological Disease
    5-HT1A modulator 2 hydrochloride, a derivative of 8-OH-DPAT (HY-112061), is a modulator of 5-HT1A with a Ki of 53 nM for 5-HT1A binding [1].
    5-HT1A modulator 2 hydrochloride
  • HY-W615853

    5-HT Receptor Others
    5-HT1A modulator 4 (Compound 1) is a ligand of 5-HT receptors. 5-HT1A modulator 4 has Ki values of 2.18 μM and 19.7 μM for 5-HT1A and 5-HT2A, respectively [1].
    5-HT1A modulator 4
  • HY-169394

    5-HT Receptor Serotonin Transporter Dopamine Receptor Neurological Disease
    5-HT1AR agonist 2 (Compound 4f) is a 5-HT1A receptor agonist (Ki: 10.0 nM). 5-HT1AR agonist 2 also binds to the SERT, D2 receptor and 5-HT6 receptor (Ki: SERT, 2.8 nM; D2, 23 nM; 5-HT6, 192 nM). 5-HT1AR agonist 2 is stabilized in microsomes and induces hypothermia in mice [1].
    5-HT1AR agonist 2
  • HY-162585

    5-HT Receptor Neurological Disease
    5-HT1AR agonist 1 (Compound A3) emerges as a relatively balanced multi-target activity profile, including 5-HT1AR agonist with an EC50 value of 34 nM, SERT reuptake ihibitor (IC50 =12 nM), NET reuptake inhibitor (IC50 =78 nM) and DAT reuptake inhibitor (IC50 =135 nM). 5-HT1AR agonist 1 performs significant antidepressant effects and exhibits excellent bioavailability and low clearance in mice, which is promising for research in the field of antidepressant drugs [1].
    5-HT1AR agonist 1
  • HY-100290

    5-HT Receptor Neurological Disease
    5-HT1A modulator 1 displays very high affinities for the 5HT1A, adrenergic α1 and dopamine D2 receptor with IC50s of 2 ±0.3 nM, 10 ± 3 nM and 40 ±9 nM, respectively.
    5-HT1A modulator 1
  • HY-162083

    Cannabinoid Receptor 5-HT Receptor Neurological Disease
    CB2R/5-HT1AR agonist 1 (Compound 2o) is an orally active partial agonist of the CB2 receptor (EC50=479.6 nM). CB2R/5-HT1AR agonist 1 is a full agonist of 5-HT1A receptor (EC50=2.7 μM). CB2R/5-HT1AR agonist 1 exhibits anti-anxiety and anti-depressive effects. CB2R/5-HT1AR agonist 1 possesses favorable pharmacokinetic properties [1].
    CB2R/5-HT1AR agonist 1
  • HY-173044

    5-HT Receptor Dopamine Receptor Neurological Disease
    5-HT1AR/5-HT6R ligand-1 (Compound PP13) is the ligand for 5-HT receptor that exhibits good affinity to 5-HT1AR, 5-HT6R and 5-HT7R (Ki of 19, 69 and 198 nM, respectively), thereby inhibiting the cAMP production in HEK293 cell with EC50 of 1535, 488 and 53 nM, respectively. 5-HT1AR/5-HT6R ligand-1 exhibits anti-proliferative activity against a variety of cancer cells (IC50 for 1321N1, U87MG, MCF7, and AsPC-1 is 9.6, 13.6, 19.3 and 14.6 μM, respectively). 5-HT1AR/5-HT6R ligand-1 also exhibits antagonist activity for dopamine receptor D2R with Ki of 1903 nM [1].
    5-HT1AR/5-HT6R ligand-1
  • HY-101208

    5-HT Receptor Neurological Disease Inflammation/Immunology
    L694247 is a selective 5-HT1D agonist with the pIC50 values of 10.03, 8.64, 6.42, and 5.66 for 5-HT1D, 5-HT1A, 5-HT1C, and 5-HT1E receptors , respectively [1].
    L694247
  • HY-116908

    5-HT Receptor Neurological Disease
    SB-272183 is a selective 5-HT1A, 5-HT1B and 5-HT1D receptor antagonist. In addition, SB-272183 is also a potent and selective ligand for 5-HT1A, 5-HT1B and 5-HT1D receptors in human recombinant and native tissues with pKi values ??of 8.0, 8.1 and 8.7, respectively. SB-272183 can be used in antidepressant research [1].
    SB-272183
  • HY-124117

    5-HT Receptor Neurological Disease
    LY 278584 is a potent, highly selective 5-HT3 receptor antagonist with a Ki of 1.62 nM. LY 278584 has no activity on 5-HT1A, 5-HT1B, 5-HT1C, 5-HT1D, or 5-HT2 receptors [1].
    LY 278584
  • HY-105082

    BMS 180048

    5-HT Receptor Cardiovascular Disease Neurological Disease
    Avitriptan is a 5-HT1B/1D receptor agonist, with pKis of 7.44 ( 5-HT1B rat), 7.68 ( 5-HT1B human) and 8.36 ( 5-HT1D human). Avitriptan constricts the isolated coronary artery. Avitriptan can be used for migraines [1].
    Avitriptan
  • HY-103151

    5-HT Receptor Neurological Disease
    CP94253 hydrochloride is a potent and selective agonist of 5-HT1B receptor (Ki= 2 nM in a radioligand binding assay).Ki values for 5-HT1A, 5-HT1D, 5-HT1C and 5-HT2 receptors are 89, 49, 860, and 1600 nM respectively [1]. CP94253 hydrochloride is centrally active upon systemic administration in vivo .
    CP94253 hydrochloride
  • HY-101698B

    Alnitidan dihydrochloride

    5-HT Receptor Neurological Disease Inflammation/Immunology
    Alniditan (Alnitidan) dihydrochloride is a potent 5-HT1B and 5-HT1D receptors agonist, with IC50s of 1.7 nM and 1.3 nM for h5-HT1B and h5-HT1D receptors in HEK?293 cells, respectively. Alniditan dihydrochloride has migraine-preventive effects [1] .
    Alniditan dihydrochloride
  • HY-101698

    Alnitidan

    5-HT Receptor Neurological Disease Inflammation/Immunology
    Alniditan (Alnitidan) is a potent 5-HT1B and 5-HT1D receptors agonist, with IC50s of 1.7 nM and 1.3 nM for h5-HT1B and h5-HT1D receptors in HEK 293 cells, respectively. Alniditan has migraine-preventive effects [1] .
    Alniditan
  • HY-B1658A

    (R)-Frovatriptan succinate hydrate; SB 209509 succinate hydrate; VML 251 succinate hydrate

    5-HT Receptor Neurological Disease
    Frovatriptan succinate hydrate ((R)-Frovatriptan succinate hydrate) is a potent, high affinity, selective and orally active 5-HT1B (pK50 of 8.2) and 5-HT1D receptor agonist. Frovatriptan succinate hydrate exhibits >10-fold selectivity for 5-HT1B and 5-HT1D over 5-HT1A, 5-HT1F, and 5-HT7 and >1000-fold selectivity over other 5-HT, dopamine, histamine H1, and α1-adrenoceptor. Frovatriptan succinate hydrate has the potential for migraine research [1] .
    Frovatriptan succinate hydrate
  • HY-B1658B

    (R)-Frovatriptan succinate; SB 209509 succinate; VML 251 succinate

    5-HT Receptor Neurological Disease
    Frovatriptan succinate ((R)-Frovatriptan succinate) is a potent, high affinity, selective and orally active 5-HT1B (pK50 of 8.2) and 5-HT1D receptor agonist. Frovatriptan succinate exhibits >10-fold selectivity for 5-HT1B and 5-HT1D over 5-HT1A, 5-HT1F, and 5-HT7 and >1000-fold selectivity over other 5-HT, dopamine, histamine H1, and α1-adrenoceptor. Frovatriptan succinate has the potential for migraine research [1] .
    Frovatriptan succinate